Free
Correspondence  |   June 2002
Which Formulation of Propofol was Used?
Author Notes
  • Northern Nevada Medical Center, Sparks, Nevada.
Article Information
Correspondence
Correspondence   |   June 2002
Which Formulation of Propofol was Used?
Anesthesiology 6 2002, Vol.96, 1529. doi:
Anesthesiology 6 2002, Vol.96, 1529. doi:
To the Editor:—
Drs. Kron, 1 Naguib, 2 and Meakin 3 discuss cases of bronchospasm associated with rapacuronium. Interestingly, all patients also received propofol. Dr. Kron also states in his discussion that propofol is “usually not associated with bronchospasm.”1 In the same issue of Anesthesiology, Brown et al.  4 describe that the metabisulfite preservative used in the newer formulation of propofol does not provide the attenuation in neurally mediated and direct airway smooth muscle-induced bronchoconstriction that is seen with propofol without metabisulfite. None of the reports of bronchospasm specified which formulation of propofol was used. While I believe that there is an association of bronchospasm with rapacuronium, the timing of the administration of propofol and rapacuronium warrants an examination of the propofol used. The release of propofol with metabisulfite in the Spring of 1999 may contribute to the observation of more cases of rapacuronium-associated bronchospasm than was seen during the period of the clinical trials.
In addition, Lewis et al.  5 suggest that the propofol formulation with metabisulfite is less potent than the propofol formulation without metabisulfite. The metabisulfite containing propofol required 10% higher induction boluses and up to 25% higher infusion rates. This suggests that some patients may have been less deeply anesthetized before instrumentation of the airway. Also, while not evident in reading the case reports, there could have been a tendency to intubate prematurely in these patients, possibly contributing to bronchospasm.
In summary, I believe rapacuronium is associated with bronchospasm, although the contribution of propofol formulation and anesthetic depth at intubation is unknown. I suggest these factors need further investigation.
References
Kron SS: Severe Bronchospasm and Desaturation in a Child Associated with Rapacuronium. A nesthesiology 2001; 94: 923–924Kron, SS
Naguib M: How Serious Is the Bronchospasm Induced by Rapacuronium? A nesthesiology 2001; 94: 924–925Naguib, M
Meskin GH, Pronske EH, Lerman J, Orr R, Joffe D, Savaree AM, Lynn AM: Bronchospasm after Rapacuronium in Infants and Children. A nesthesiology 2001; 94: 926–927Meskin, GH Pronske, EH Lerman, J Orr, R Joffe, D Savaree, AM Lynn, AM
Brown RH, Greenberg RS, Wagner EM: Efficacy of propofol to prevent bronchoconstriction: effects of preservative. A nesthesiology 2001; 94: 851–5; discussion 6ABrown, RH Greenberg, RS Wagner, EM
Lewis TC, Janicki PK, Higgins MS, Szmyd-Hogan K, Beattie C: Anesthetic Potency of Propofol With EDTA Versus Sulfite-Containing Propofol in Patients Undergoing Magnetic Resonance Imaging: A Retrospective Analysis. Am J Anesthesiol 2000, 27,6S: 30–32Lewis, TC Janicki, PK Higgins, MS Szmyd-Hogan, K Beattie, C